



10-753-1632  
9/27/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel & Reynolds

FILED: February 14, 2002

SERIAL NO.: 10/075,322

FOR: Combined Transductional and  
Transcriptional Targeting System  
For Improved Gene Delivery

§  
§  
§  
§  
§  
§  
§  
§  
§

ART UNIT: RECEIVED

AUG 20 2002

EXAMINER:

TECH CENTER 1600/2900

DOCKET:  
D 6392

Honorable Commissioner of Patents  
Box DD  
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

Dear Sir:


I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: Honorable Commissioner of Patents, BOX DD, Washington, DC 20231.


- 1) Information Disclosure Statement;
- 2) Information Disclosure Statement Cover Letter;
- 3) PTO Form 1449 (Six References cited); and
- 4) Postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Aug 12, 2002  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391  
BADLER1@houston.rr.com

  
Benjamin Aaron Adler, Ph.D., J.D.  
Counsel for Applicant  
Registration No. 35,423



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel & Reynolds

FILED: February 14, 2002

SERIAL NO.: 10/075,322

FOR: Combined Transductional and  
Transcriptional Targeting System  
For Improved Gene Delivery

Honorable Commissioner of Patents  
Box DD  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)  
AND STATEMENT UNDER 37 CFR 1.97(e)(1)

Dear Sir:

Enclosed herewith for filing under 37 C.F.R. 1.97(c) in the above-referenced matter is form PTO-1449 together with copies of the references listed therein. Applicants state that each item of information contained in the information disclosure statement herein was cited in a communication from a foreign application not more than three months prior to the filing of the information disclosure statement. If any questions remain, the Examiner is respectfully requested to call the undersigned attorney at (713)-270-5391.

Date: Aug 12, 2002  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391  
BADLER1@houston.rr.com

§ ART UNIT:  
§  
§  
§  
§  
§  
§  
§  
§

EXAMINER:


DOCKET:  
D6392

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

Respectfully submitted,

  
Benjamin Aaron Adler, Ph.D., J.D.  
Counsel for Applicant  
Registration No. 35,423



## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure  
Statement

DOCKET NO.: D6392  
SERIAL NO.: 10/075,322  
APPLICANT: Curiel & Reynolds  
FILING DATE: February 14, 2002  
GROUP:

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
	5,871,727	2/16/99	Curiel	424/93.2	514/44	12/6/96
	5,846,782	12/8/98	Wickham	435/697	530/350	8/21/96
	5,837,283	11/17/98	McDonald	424/450	935/54	3/12/97

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)  
Translation: English  
Document Number: WO 99/36545 Date: 7/22/99 ✓  
Country: Grate Britain  
Class Or Subclass C12N 15/86  
Patent: Yes \_ No X  
Title: Adenoviral Vectors With Modified Capsid Proteins

## OTHER DOCUMENTS (Including Author, Title, Place of Date, Publication)

✓ a. Reynolds, P. *et al.* Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnology, vol. 19, 2001, pp. 838-842.

✓ b. Muzykantov, Vladimir R. Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. American Physiological Society, 1996, pp. L704-L713

Examiner

Date Considered

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)